Seelos Therapeutics, Inc.
SEEL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2,203 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $30,117 | $53 | $0 | $0 |
| Gross Profit | -$27,914 | -$53 | $0 | $0 |
| % Margin | -1,267.1% | – | – | – |
| R&D Expenses | $30,117 | $58,620 | $46,649 | $10,984 |
| G&A Expenses | $12,585 | $12,296 | $15,020 | $7,775 |
| SG&A Expenses | $12,528 | $12,296 | $15,020 | $7,775 |
| Sales & Mktg Exp. | -$57 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $230 | $0 |
| Operating Expenses | $12,585 | $70,916 | $61,669 | $18,759 |
| Operating Income | -$40,499 | -$70,916 | -$61,669 | -$18,759 |
| % Margin | -1,838.4% | – | – | – |
| Other Income/Exp. Net | $2,617 | -$2,618 | -$4,379 | -$342 |
| Pre-Tax Income | -$37,882 | -$73,534 | -$66,048 | -$19,101 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37,882 | -$76,138 | -$67,533 | -$19,220 |
| % Margin | -1,719.6% | – | – | – |
| EPS | -7.73 | -21.48 | -22.29 | -12.88 |
| % Growth | 64% | 3.6% | -73.1% | – |
| EPS Diluted | -7.73 | -21.48 | -22.29 | -12.88 |
| Weighted Avg Shares Out | 4,900 | 3,545 | 3,030 | 1,492 |
| Weighted Avg Shares Out Dil | 4,900 | 3,545 | 3,030 | 1,492 |
| Supplemental Information | – | – | – | – |
| Interest Income | $198 | $121 | $113 | $45 |
| Interest Expense | $75 | $14 | $1,598 | $164 |
| Depreciation & Amortization | $57 | $53 | $61,669 | $18,759 |
| EBITDA | -$37,750 | -$73,467 | $0 | $0 |
| % Margin | -1,713.6% | – | – | – |